Selection of optimal antisense accessible sites of survivin and its application in treatment of gastric cancer

Figure 1 Secondary structure of antisense accessible sites (4-23 bp) of survivin designed only with RNADraw software.

Figure 2 Primer extension analysis for the selection of antisense accessible sites of survivin by random oligonucleotide library/RNase H cleavage method. M: PhiX174 Hinf I DNA marker. Lane 1: Primer extension positive control; lanes 2-3: Primer extension products of P₁ and P₂ .

Figure 3 Four secondary structures of antisense accessible sites predicted by RNADraw software. A: ODN₁ (207-226 bp); B: ODN₂ (187-206 bp); C: ODN₃ (126-145 bp); D: ODN₄ (44-63 bp).

Figure 4 RT-PCR and Western blotting detection of the blocking effects of various antisense oligonucleotides on survivin mRNA and protein expression of MKN-45 cells. A: RT-PCR detection of the blocking effects of various antisense oligonucleotides on survivin mRNA expression of MKV-45 cells M: PCR marker (100-1000 bp). Lane 1: Non-transfection Control; lane 2: AS-ODN₀; lane 3: AS-ODN₁ ; lane 4: AS-ODN₂; lane 5: AS-ODN₃; lane 6: AS-ODN₄; B: Western blotting detection of the blocking effects of various antisense oligonucleotides on survivin protein expression of MKN-45 cells.

Figure 5 Growth inhibitory effects of various antisense oligonucleotides on MKN-45 cells.

Figure 6 Morphological observation of gastric cancer cells after transfection with antisense oligonucleotides targeting survivin by electronic microscopy.

Figure 7 Flow cytometry detection of apoptosis-inducing effects of various antisense oligonucleotides on MKN-45 cells.